课题基金 / 基金详情

GTP-BINDING PROTEIN STRUCTURE/FUNCTION STUDIES

GTP-BINDING PROTEIN STRUCTURE/FUNCTION STUDIES
GTP 结合蛋白结构/功能研究
批准号:
2576750
负责人:
M VAUGHAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

M VAUGHAN的其他基金

相似基金

相关文献

中文摘要
翻译
ADP-核糖化因子(ARF)是一个高度保守的家族,约有20个 刺激霍乱毒素(CT)的KDA-鸟嘌呤核苷酸结合蛋白 体外活性,是众所周知的特定囊泡的调节剂 贩卖人口事件。与GTP结合的ARF处于活性构象, 与可促进其相互作用的膜结合 几种可能的效应器,例如GTP结合蛋白激活的 磷脂酶D(PLD)的异构体。为了努力确定 ARF负责它与效应器的相互作用,我们产生了氨基- 末端截断的ARF、嵌合ARF和点突变体。氨基- ARF1的末端截断显著降低了它的激活能力 PLD,但不是它与GTP结合的能力。嵌合蛋白,来源于 ARF1和人类ARF样蛋白(ARL1),这是一种导致最低限度 激活PLD,以前都被用来建立氨基酸1 到73个ARF参与PLD的激活,以及74-181个氨基酸 都参与了CT的激活。嵌合构建物ARF28ARL(The ARF1的氨基末端28个氨基酸加上羧基末端153个氨基酸 ARL1的酸)激活PLD的能力弱于ARF50ARL 建造。因此,氨基酸28和50之间的残基不同于 ARF和ARL参与了PLD的激活,而且似乎 ARF至少有两个不同的区域参与激活 可编程逻辑器件。 近年来,ARF与异三聚体G蛋白相互作用的研究进展 β/γ亚基被证明在内体融合中发挥作用, 与这些主要调控蛋白之间的串扰一致。至 测试ARF与CT通过类似序列相互作用的可能性 到β/伽马相互作用区,它存在于β-肾上腺素能 受体激酶(BetaARK),而不是视紫红质激酶(RK),我们利用 由BetaARK、RK和ARF以及多肽组成的融合蛋白结构 与假定的相互作用序列相关联。GST-BetaARK和BetaARK派生 多肽抑制ARF对CT的刺激,而GST-RK不抑制。 此外,与ARF的C-末端一半相对应的融合蛋白 也可抑制ARF对CT的刺激。基于这些和之前的研究 对于ARF-ARL嵌合蛋白,似乎ARF中的序列 类似于BetaARK的β/伽马相互作用部位可以影响 霍乱毒素与ARF的相互作用。
英文摘要
ADP-ribosylation factors (ARFs), a highly conserved family of about 20 kDa-guanine nucleotide-binding proteins that stimulate cholera toxin (CT) activity in vitro, are well known regulators of specific vesicular trafficking events. ARF with GTP bound is in an active conformation and associates with membranes which may facilitate its interaction with one of several possible effectors, such as the GTP-binding protein-activated isoform of phospholipase D (PLD). In an effort to identify domains of ARF responsible for its interaction with effectors, we generated amino- terminally truncated ARFs, chimeric ARFs and point mutants. Amino- terminal truncation of ARF1 significantly reduced its ability to activate PLD, but not its ability to bind GTP. Chimeric proteins, derived from ARF1 and human ARF-like protein (ARL1), a protein that causes minimal activation of PLD, were previously used to establish that amino acids 1 to 73 of ARF are involved in PLD activation and that amino acids 74-181 are involved in CT activation. The chimeric construct ARF28ARL (the amino-terminal 28 amino acids of ARF1 plus the carboxy-terminal 153 amino acids of ARL1) had less ability to activate PLD than did an ARF50ARL construct. Thus, residues between amino acids 28 and 50 that differ in ARF and ARL, are involved in the activation of PLD and it appears that at least two distinct regions of ARF are involved in the activation of PLD. Recently, the interaction of ARF with the heterotrimeric G-protein beta/gamma subunits was shown to play a role in endosome fusion, consistent with cross-talk between these major regulatory proteins. To test the possibility that ARF interacts with CT via a sequence similar to the beta/gamma-interaction region, which is present in beta-adrenergic receptor kinase (betaARK), but not in rhodopsin kinase (RK), we utilized fusion protein constructs of betaARK, RK, and ARF, as well as peptides with the putative interaction sequence. GST-betaARK and betaARK-derived peptides inhibited ARF stimulation of CT, whereas GST-RK did not. Moreover, a fusion protein corresponding to the C-terminal half of ARF also inhibited ARF stimulation of CT. Based on these and prior studies with ARF-ARL chimeric proteins, it appears that the sequence in ARF that is similar to the beta/gamma-interaction site of betaARK can affect cholera toxin - ARF interactions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MOLECULAR AND BIOCHEMICAL CHARACTERIZATION OF GTP-BINDING PROTEIN
MOLECULAR AND BIOCHEMICAL CHARACTERIZATION OF GTP-BINDING PROTEIN
REGULATION OF GTP BINDING PROTEINS
GTP-BINDING PROTEIN STRUCTURE/FUNCTION STUDIES
海外基金